Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Humira

 
National Institutes of Health

Related topics

Related topics

4 relations
0.2 ML adalimumab 50 MG/ML Prefilled Syringe [Humira]0.4 ML adalimumab 50 MG/ML Prefilled Syringe [Humira]0.8 ML adalimumab 50 MG/ML Injection [Humira]

Broader (1)

adalimumab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Top drugs and companies by sales in 2018
  • Lisa Urquhart
  • Nature Reviews Drug Discovery
  • 2019
    • Corpus ID: 87739243
the biggestselling drug list again in 2018, it is hard to see where any challenger might come from to snatch the autoimmune… Expand
  • figure 1
Highly Cited
2018
Highly Cited
2018
Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase…
Objective To demonstrate clinical equivalence of adalimumab biosimilar candidate BI 695501 with Humira. Methods Patients with… Expand
2017
2017
Demonstration of physicochemical and functional similarity between the proposed biosimilar adalimumab MSB11022 and Humira®
ABSTRACT Biosimilars are biological products that are highly similar to existing products approved by health authorities… Expand
2017
2017
Pharmacokinetics, safety, tolerability and immunogenicity of FKB327, a new biosimilar medicine of adalimumab/Humira, in healthy subjects
AIMS To compare the pharmacokinetics, safety, tolerability and immunogenicity of FKB327, a biosimilar of adalimumab, with… Expand
  • table 1
  • figure 1
  • table 2
  • table 3
  • table 4
2016
2016
A prospective, randomized, double‐blind, multicentre, parallel‐group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC‐3197) and adalimumab (Humira) in…
In this study, efficacy, tolerability and safety of biosimilar adalimumab (Exemptia; Zydus Cadila) was compared with reference… Expand
2016
2016
Comparison of the pharmacokinetics, safety, and immunogenicity of MSB11022, a biosimilar of adalimumab, with Humira® in healthy subjects
Aims The aim of the study was to compare the pharmacokinetics (PK), safety and tolerability of the proposed adalimumab biosimilar… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Review
2016
Review
2016
Humira: the impending patent battles over adalimumab biosimilars.
  • P. Norman
  • Pharmaceutical patent analyst
  • 2016
    • Corpus ID: 29403624
The world's top selling drug, adalimumab (AbbVie's Humira), generated sales in excess of US$13 billion in 2015. The primary… Expand
2012
2012
Die‐Off Ratio Correlates with Increased TNF‐α:IL‐10 Ratio and Decreased IVF Success Rates Correctable with Humira
Human embryos develop at varying rates in culture, with only a fraction of the eggs retrieved developing to ‘transfer quality… Expand
2011
2011
Birth Defect Rates in Women Using Adalimumab (Humira®) to Treat Immunologic‐Based Infertility in IVF Patients
Citation Winger EE, Reed JL, Ashoush S, El‐Toukhy T, Ahuja S, Taranissi M. Birth defect rates in women using Adalimumab (Humira… Expand
2004
2004
Humira (adalimumab).
FDA-Approved Indications  Moderately to severely active rheumatoid arthritis (RA)  Moderately to severely active polyarticular… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE